GRAIL anticipates early Q1 2027 FDA decision while updating 2026 Galleri revenue growth to 17%-21%
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Finance & Markets
Colgate-Palmolive vs. Hershey: Which Consumer Goods Stock Is the Better Buy for 2027?
Key PointsColgate-Palmolive’s trailing-12-month revenue grew about 6% to $21 billion, with $3.8 billion in free cash flow.
Razorpay gets SEBI approval for IPO, eyeing $5b valuation
Razorpay’s revenue grew 24% in FY24 to 20.7 billion rupees (US$219 million).